株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬剤充填済み注射器の主要製造業者:2016年〜2026年 - 主要シリンジ・注射器・部品メーカー・受託製造業者 (CMO) のプロファイル・研究開発および収益予測

Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 - Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Manufacturers (CMOs);

発行 Visiongain Ltd 商品コード 234469
出版日 ページ情報 英文 231 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.80円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
薬剤充填済み注射器の主要製造業者:2016年〜2026年 - 主要シリンジ・注射器・部品メーカー・受託製造業者 (CMO) のプロファイル・研究開発および収益予測 Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 - Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Manufacturers (CMOs);
出版日: 2016年08月03日 ページ情報: 英文 231 Pages
概要

当レポートでは、薬剤充填済み注射器関連の主要製造業者25社の評価と業界全体の分析 (販売実績・収益予測・成長率) 、研究開発動向などについて調査しています。

第1章 レポートの概要

第2章 薬剤充填済み注射器のイントロダクション

  • 薬剤充填済み注射器とは
  • 薬剤充填済み注射器メーカーの分類
    • ペン型注射器と自動注射器
    • 薬剤充填済み注射器のメリット・デメリット
  • 市場予測
  • 薬剤充填済み注射器市場の1部門としての受託製造
  • 西側市場での需要が最大
  • 主要動向の予測

第3章 薬剤充填済みシリンジの主要メーカー

  • Becton, Dickinson & Co (BD)
  • Gerresheimer
  • Schott
  • ニプロ
  • Stevanato Group/Ompi
  • 競合分析
  • 高い参入障壁が競争を制限
  • その他の有力メーカー

第4章 薬剤充填済み注射器部品の主要メーカー

  • Aptar Stelmi
  • Datwyler Holding
  • West Pharmaceutical Services
  • 競合分析

第5章 ペン型注射器・自動注射器の主要メーカー

  • Haselmeier
  • Owen Mumford
  • SHL Group
  • Ypsomed
  • 競合分析

第6章 薬剤充填済み注射器の主要受託製造業者

  • Catalent
  • Hospira One2One
  • Vetter Pharmaceutical
  • 競合の見通し
  • その他の受託製造業者

第7章 リサーチインタビュー

  • Gerresheimerへのインタビュー

第8章 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0135

Pre-Filled Syringes and Related Drug Delivery - Discover Leading Companies' Revenue Potentials

How are companies in the pre-filled syringe industry performing? Visiongain's new report gives you data, analysis and discussions for producers of those drug delivery devices.

Our study lets you assess companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2026. There you see financial results, opinion, trends, opportunities and sales predictions.

That way you discover potentials of established and rising companies. Read on, please, to scan those organisations and see what their future market could be worth.

Forecasts and discussions to help you stay ahead in knowledge and authority

Our new study assesses 25 top companies - and analyses that overall industry - with sales results, revenue forecasts and growth rates. In our 230 page report you gain 86 tables, 30 charts and a research interview.

You also get qualitative analyses, including research and development. Our work lets you assess the most beneficial and lucrative applications of those drug delivery technologies. There you see opportunities for producers of medical injection devices and manufacturers of biologics, insulins and vaccines.

That way you stay ahead in knowledge of the industry and market for these medical devices, helping your influence. You explore leading developers, producers and marketers of these products:

  • Plastic and glass pre-filled syringes
  • Pen injectors and autoinjectors, including insulin delivery
  • Related components and safety systems, including needles, shields, Luer fitments, plungers and tip caps
  • Contract manufacturing organisations (CMOs) providing filling services for pre-filled injection devices (syringes and cartridges).

The following sections describe how our new investigation helps your work.

Company profiles - discover why firms succeed, also exploring their prospects

Our report profiles 25 leading companies worldwide across four segments of the pre-filled injection devices market. The content of each discussion differs, depending on the company. In general a profile contains the following information:

  • Overview of the firm, showing its place in the pre-filled injection devices field
  • Discussion of the company's product or service portfolio, including clients
  • Analysis of the player's recent financial performance, esp. relevant sales
  • Coverage of developments - e.g. acquisitions, R&D, expansions, launches and collaborations with the pharmaceutical industry
  • Prospects of the company - strengths over competitors and opportunities
  • Prediction of revenue for the period 2016-2026 (for 10 companies).

Our survey shows how product and service demand changed in recent years, as well as explaining how those needs can develop from 2016 - rising demand.

image1

Prospects for leading pre-filled syringe manufacturers

Our study gives you discussions and financial analyses for developers and producers of pre-filled injection devices - these five leaders and other firms:

  • Becton, Dickinson & Co. (BD)
  • Gerresheimer
  • Schott
  • Nipro
  • Ompi.

There you discover what the future holds for those medical device companies, seeing how they compare and compete. You find where the best prospects for business exist.

Suppliers and users of pre-filled injection systems will benefit from 2016. Next, our work analyses developers, producers and providers of associated technology.

Outlooks for manufacturers of pre-filled syringe components

The report shows you developments and revenue prospects for leading producers of syringe components and related accessories, including these companies:

  • Aptar Stelmi
  • Dätwyler Holding
  • West Pharmaceutical Services.

In our study you explore opportunities for companies making injection safety systems, plungers, needle shields, caps and related products.

Our work shows you where sales growth can occur. Many opportunities remain, with expanding revenues likely from 2016 to 2026. See what is possible.

Potentials of leading pen injector and autoinjector producers

In our study you also see commercial outlooks for top manufacturers of pen injectors and autoinjectors, including these companies:

  • Haselmeier
  • Owen Mumford
  • SHL Group
  • Ypsomed.

There you assess product portfolios, strategies and revenue prospects. You also investigate associated organisations and competition. Our work shows you possibilities for advancing technologies and raising sales.

Contract manufacturers in that parenteral drug delivery

Our work also assesses contract manufacturing organisations (CMOs) in that field. There you explore these production service providers and others:

  • Catalent
  • Hospira One2One
  • Vetter Pharma.

That way you assess the capabilities and outlooks of healthcare CMOs in that field. You also scan applications for biological drugs (biologics), lyophilisation and dual-chamber syringes, among other advances.

Value of that market in 2020 - what sales growth is possible and why?

Our analysis predicts overall world revenues for those pre-filled injection devices - the drug delivery technology - will reach $6940m in 2020. Those sales will expand further to 2026, showing strong revenue growth. Many opportunities remain.

Greater use of biologics and vaccines raise demand for parenteral delivery systems. Many opportunities exist, especially for plastic syringes, polymers and ready-to-use containment of labile drugs and other complex pharmaceuticals. Our study explains.

What about applications? Rising incidence of diabetes and expansion of the home healthcare market stimulate demand for pre-filled injection products. Explore what is possible, staying ahead. In our study you see what those companies' futures hold.

5 ways Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 helps your work

In particular our new investigation gives you this knowledge to benefit your research, analyses, plans and presentations:

  • Profiles of 25 leading companies - assess their products, technologies, activities, partnerships, developments and results
  • Forecast revenue to 2026 for that overall market at world level - discover expected sales rises for pre-filled drug delivery devices and services
  • Predicted revenues for top companies - see potential sales to 2026 for 10 leading participants
  • Competition and opportunities - explore what affects that industry, seeing forces that influence its sales and determine its future
  • Opinion from an interview with a leading company - gain insight to help you stay ahead in knowledge, benefiting your reputation for insight.

That study, by our in-house analysts in the UK, has the purpose of helping your work. There you gain data and insight you find nowhere else, to help you succeed.

Independent analysis to benefit your authority on pre-filled drug delivery

Our work gives independent analysis. There you receive business intelligence found only in that report, seeing where technological and financial prospects are most rewarding, as well as companies' potentials from 2016 to 2026.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and gaining in authority. Explore that industry's future, seeing what is possible and how you can gain.

Table of Contents

1. Report Overview

  • 1.1 Global Pre-Filled Injection Devices Market Overview
  • 1.2 Pre-Filled Injectable Devices Market Segmentation
  • 1.3 Top Pre-Filled Injectable Devices Market: An Overview
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Pre-Filled Injectable Devices

  • 2.1 What are Pre-Filled Injectable Devices?
  • 2.2 Classification of Companies in the Pre-Filled Injectable Devices Market
    • 2.2.1 Pen Injectors and Autoinjectors
    • 2.2.2 Benefits and Weaknesses of Pre-Filled Injectors
  • 2.3 The Pre-Filled Injection Devices Market 2016-2026
  • 2.4 Contract Manufacturing as a Sector of the Pre-Filled Injectable Devices Market
  • 2.5 Demand on the Western Market is the Highest
  • 2.6 Key Trends in the Pre-Filled Injection Device Market 2016-2026
    • 2.6.1 Increased Market Consolidation
    • 2.6.2 Increased Development of Biologics and Biosimilars
    • 2.6.3 Rise In At Home Care
    • 2.6.4 Greater Demands for Safety Leading Innovation
    • 2.6.5 Threat from Other Drug Delivery Technologies

3. Leading Companies in the Pre-Filled Syringes Manufacturing Market 2016-2026

  • 3.1 Becton, Dickinson, & Co (BD)
    • 3.1.1 BD: Broad Portfolio of Syringe Products
      • 3.1.1.1 BD Hypak: The First Glass Pre-Filled Syringe Worldwide
      • 3.1.1.2 BD Sterifill
      • 3.1.1.3 BD Soluvia
      • 3.1.1.4 BD Uniject on the Emerging Market
      • 3.1.1.5 BD Physioject Autoinjector
      • 3.1.1.6 BD Nano 4mm Pen Needles
      • 3.1.1.7 BD Pen Injectors: BD Liquid Dry Injector and BD Reusable Pen
      • 3.1.1.8 BD Vystra Disposable Pen
      • 3.1.1.9 BD Neopak
      • 3.1.1.10 BD Proprietary Syringe Safety Systems
      • 3.1.1.11 The BD Emerald Portfolio
    • 3.1.2 New Product Launches Planned
    • 3.1.3 BD Acquires Safety Syringes
    • 3.1.4 BD's Pre-Filled Injection Historical Revenue 2014-2015
    • 3.1.5 Major Acquisitions and Focus on Core Competencies
    • 3.1.6 BD's Main Strategic Goals
    • 3.1.7 BD: Trend for Strategic Partnering
    • 3.1.8 BD SWOT Analysis, 2016-2026
      • 3.1.8.1 Collaboration and Expansion: Strategies for Growth and Rebranding
      • 3.1.8.2 BD Medical Revenue Forecast 2015-2026
  • 3.2 Gerresheimer
    • 3.2.1 Pre-Filled Syringe Manufacture at Gerresheimer
      • 3.2.1.1 RTF (Ready-To-Fill) Glass Syringes at Gerresheimer
      • 3.2.1.2 ClearJect RTF Plastic Syringes at Gerresheimer
      • 3.2.1.3 New German-made RTF ClearJect Syringe Combines the RTF Concept with Plastic
    • 3.2.2 Pen Injector Manufacture at Gerresheimer
    • 3.2.3 Gerresheimer Historical Revenue 2014-2015
    • 3.2.4 Strategic Sale of Glass Tubing Business: Company Focus on Medical Devices and Primary Packaging
    • 3.2.5 Strong Growth in the Plastics and Devices Division with a Focus on Modernisation
    • 3.2.6 Standardisation as a Strategy
    • 3.2.7 Gerresheimer SWOT Analysis, 2016-2026
      • 3.2.7.1 Rapid Growth Planned for Emerging Markets
      • 3.2.7.2 Gerresheimer is Well-Placed for Biologics Growth and More Stringent Regulatory Changes
      • 3.2.7.3 Gerresheimer Pen Injector Market Revenue Forecast 2015 to 2026
  • 3.3 Schott
    • 3.3.1 Schott Markets Glass and Plastic Pre-Filled Syringes
      • 3.3.1.1 Glass Syringes at Schott: Forma 3s and syriQ
      • 3.3.1.2 TopPac Polymer Syringes
      • 3.3.1.3 InJentle Syringes for Sensitive Drug Products
      • 3.3.1.4 Other New Innovations at Schott
    • 3.3.2 Schott Historical Revenue
    • 3.3.3 Expansion in Developed and Emerging Markets
      • 3.3.3.1 Growth in the Emerging Market
    • 3.3.4 Schott SWOT Analysis, 2016-2026
      • 3.3.4.1 Schott's Emerging Market Strategy
  • 3.4 Nipro Medical Corporation
    • 3.4.1 Overview of Nipro's Pre-Filled Syringe Portfolio
    • 3.4.2 New Products at Nipro
    • 3.4.3 Nipro is Expanding Globally
    • 3.4.4 Nipro SWOT Analysis, 2016-2026
      • 3.4.4.1 Responding to Rising Diabetes Incidence
  • 3.5 Stevanato Group/Ompi
    • 3.5.1 Ompi Markets Glass Pre-Filled Syringes and Cartridges
      • 3.5.1.1 EZ-Fill Syringe
      • 3.5.1.2 Extra High Quality (XQ) Syringes
      • 3.5.1.3 Acquisitions and Innovations at Ompi
    • 3.5.2 Focused on Growth for Cartridges and Vials Manufacturing Especially in Emerging Markets
    • 3.5.3 Ompi SWOT Analysis, 2016-2026
      • 3.5.3.1 Ompi's Products for the Biologics Market
      • 3.5.3.2 Investing to Expand Capacity and Deal with Increasing Demand
  • 3.6 Pre-Filled Syringe Manufacturers: Competitor Analysis 2016 to 2026
    • 3.6.1 The Need for Advanced Safety Systems
    • 3.6.2 Meeting the Demands of Biologics and Biosimilar Developers
    • 3.6.3 Product Portfolio Diversity
    • 3.6.4 What Demand is there in Emerging Markets?
  • 3.7 High Barriers to Market Entry Will Limit Competition to 2026
  • 3.8 Other Manufacturers of Interest in this Market
    • 3.8.1 Unilife
      • 3.8.1.1 Unilife's Many Collaborations
      • 3.8.1.2 Unilife's Historical Revenue 2013-2015
    • 3.8.2 Revolutions Medical: A Disposable Syringe Manufacturer Entering the Pre-Filled Market
    • 3.8.3 Weigao Group Pharmaceutical Packaging Products Company
      • 3.8.3.1 Weigao's Historical Revenue 2013-2015
      • 3.8.3.2 Weigao Pre-Filled Syringes Revenue Forecast 2015-2026
    • 3.8.4 Roselabs Group

4. Leading Companies in the Pre-Filled Injectable Components Manufacturing Market

  • 4.1 Aptar Stelmi is a Pharma Packaging Specialist
    • 4.1.1 Aptar Stelmi's Pre-Filled Syringe Components
      • 4.1.1.1 Aptar Stelmi's Rigid Needle Shields
    • 4.1.2 Aptar: Strategically Increasing Market Access to the Autoinjector Market
    • 4.1.3 Aptar Stelmi's Expansion and Innovations
    • 4.1.4 Aptar Stelmi's Historical Revenue 2013-2015
    • 4.1.5 Aptar Stelmi SWOT Analysis, 2016-2026
      • 4.1.5.1 Regional Expansion is Important for Continued Growth
    • 4.1.6 Aptar Stelmi Revenue Forecast 2015-2026
  • 4.2 Dätwyler Holding
    • 4.2.1 Dätwyler's Pre-Filled Syringe Components
    • 4.2.1.1 Omniflex Coating: An Alternative to Silicone Oil
    • 4.2.2 Demand from Insulin Manufacturers Drives Revenue Growth 2013-2015
    • 4.2.3 Dätwyler is Focused on Strategic Acquisition and Expansion
    • 4.2.4 Growth in Emerging Markets
    • 4.2.5 Dätwyler SWOT Analysis, 2016-2026
    • 4.2.6 Dätwyler Healthcare Revenue Forecast 2015-2026
  • 4.3 West Pharmaceutical Services
    • 4.3.1 West Manufactures Syringes and Syringe Components
      • 4.3.1.1 Daikyo Crystal Zenith: Licensed from Daikyo Seiko
      • 4.3.1.2 MixJect for Lyophilised Drugs
      • 4.3.1.3 West's Self-Injection Systems
      • 4.3.1.4 West Markets Three Safety Systems
      • 4.3.1.5 Innovation and Investment at West
    • 4.3.2 Recent Financial Performance
    • 4.3.3 Collaborations with Big Pharma for Product Development
    • 4.3.4 Expansion at West
    • 4.3.5 West SWOT Analysis, 2016-2026
    • 4.3.6 West Pharmaceutical Revenue Forecast 2015-2026
  • 4.4 Pre-Filled Syringe Component Manufacturers: Competitor Analysis 2016-2026
    • 4.4.1 How Can Component Manufacturers React to Increased Safety Demands?
    • 4.4.2 Other Manufacturers of Interest in this Market
      • 4.4.2.1 Tip-top: Three Safety Products for Pre-Filled Syringes
      • 4.4.2.2 Nemera: Formed from Rexam's Sale of Healthcare Division
    • 4.4.3 Entering the Autoinjector Market
    • 4.4.4 Component Manufacturers Following Pre-Filled Syringe Manufacturers to Emerging Markets

5. Leading Companies in the Pen Injector and Autoinjector Manufacturing Market 2016-2026

  • 5.1 Haselmeier
    • 5.1.1 Haselmeier Markets Five Injection Systems
      • 5.1.1.1 Axis Pen Systems
      • 5.1.1.2 i-Pen: Haselmeier's Insulin Pen Injector
    • 5.1.2 Company Growth in Germany and India
    • 5.1.3 Haselmeier SWOT Analysis, 2016-2026
  • 5.2 Owen Mumford
    • 5.2.1 Autoinjector and Pen Injector Overview
      • 5.2.1.1 Autoject
      • 5.2.1.2 Autopen
      • 5.2.1.3 SimpleJect: Designed for RA Patients
    • 5.2.2 Innovative Products to Drive Growth
    • 5.2.3 Expanding in Established and New Markets
    • 5.2.4 Owen Mumford SWOT Analysis 2016-2026
  • 5.3 SHL Group
    • 5.3.1 SHL Manufactures a Broad Range of Injection Devices
      • 5.3.1.1 DAI Autoinjectors
    • 5.3.2 SHL Group Continues to Grow in Taiwan
    • 5.3.3 SHL Group SWOT Analysis, 2016-2026
  • 5.4 Ypsomed
    • 5.4.1 Product Portfolio
      • 5.4.1.1 YpsoPen
      • 5.4.1.2 ServoPen
      • 5.4.1.3 UnoPen
      • 5.4.1.4 LyoTwist Injectors for Lyophilised Drugs
      • 5.4.1.5 Ypsomed Markets Two Autoinjectors
      • 5.4.1.6 Expansion at Ypsomed: Current and Future Plans
    • 5.4.2 Ypsomed: Financial Performance 2013-2015
    • 5.4.3 A Focus on Diabetes
    • 5.4.4 Ypsomed SWOT Analysis, 2016-2026
    • 5.4.5 Ypsomed Delivery Devices Revenue Forecast 2015-2026
  • 5.5 Pen Injector and Autoinjector Manufacturers: Competitor Analysis 2015-2026
    • 5.5.1 A Competitive Market 2016-2026
    • 5.5.2 Other Manufacturers of Interest in this Market
      • 5.5.2.1 Bespak Injectables
    • 5.5.3 How Are Companies Differentiating Their Autoinjectors?
    • 5.5.4 Rising Demand in At-Home Care
      • 5.5.4.1 Specific Demands in RA and MS
    • 5.5.5 Contract Manufacturing for Autoinjectors

6. Leading Companies in the Contract Pre-Filled Injectable Devices Manufacturing Market 2016-2026

  • 6.1 Catalent is the World's Largest CMO
    • 6.1.1 Pre-Filled Syringe Contract Manufacturing Capabilities
    • 6.1.2 Catalent Offers an Autoinjector
    • 6.1.3 Innovations at Catalent
    • 6.1.4 Catalent Pharma Solutions: Financial Performance 2013-2015
    • 6.1.5 Expanding Filling Capacity for Clinical Trial Materials
    • 6.1.6 Possible Acquisition of Catalent by Lonza
    • 6.1.7 Catalent SWOT Analysis 2016-2026
    • 6.1.8 Catalent Pre-Filled Syringe and Cartridge Filling Revenue Forecast 2015-2026
  • 6.2 Hospira One2One
    • 6.2.1 Hospira and the Pre-Filled Injection Device Industry
      • 6.2.1.1 iSecure Syringe: Hospira's Pre-Filled Injection System
    • 6.2.2 Hospira: Uncertain Future
    • 6.2.3 Hospira SWOT Analysis, 2016-2026
    • 6.2.4 Hospira One2One: Pre-Filled Injection Device Revenue Forecast 2015-2026
  • 6.3 Vetter Pharmaceutical
    • 6.3.1 Vetter is an Injectable Manufacturing Specialist
    • 6.3.2 Vetter's Ten Year Expansion Plan
    • 6.3.3 New Services and Collaborations
    • 6.3.4 Vetter SWOT Analysis 2016 to 2026
    • 6.3.5 Outlook for Vetter: Pre-Filled Injection Device Revenue Forecast 2015-2026
  • 6.4 The Competitive Outlook for Leading CMOs in the Market 2016-2026
    • 6.4.1 Biologics, Lyophilisation, and Dual-Chamber Syringes
    • 6.4.2 An Increasingly Competitive Market
    • 6.4.3 Important of Keeping Up with Regulations
  • 6.5 Other Pre-Filled Syringe Contract Manufacturers 2016
    • 6.5.1 Laboratorios Farmacéuticos ROVI
      • 6.5.1.1 ROVI CM's Pre-Filled Syringe Capabilities
    • 6.5.2 Albany Molecular Research Inc (AMRI): Strategic Acquisitions
      • 6.5.2.1 AMRI's Recent Financial Performance
    • 6.5.3 Boehringer Ingelheim

7. Research Interviews

  • 7.1 Interview with Gerresheimer
    • 7.1.1 Drivers and Restraints in the Pre-Filled Devices Market
    • 7.1.2 Pre-Filled Medical Device Development at Gerresheimer
    • 7.1.3 Future Trends in the Pre-Filled Medical Devices Market

8. Conclusions

  • 8.1 Outlook for the Pre-Filled Injection System Market 2016-2026
  • 8.2 Outlook for Leading Pre-Filled Injection System Manufacturers 2016-2026
    • 8.2.1 How Will Leading Companies' Revenues Grow to 2026?
  • 8.3 The Future of the Pre-Filled Medical Devices Market

List of Tables

  • Table 1.1 Currency Exchange Rates
  • Table 2.1 Total Pre-Filled Device Manufacturing Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 2.2 Pre-Filled Injection Device Market by Region, 2015
  • Table 2.3 Pre-Filled Injection Device Market: STEP Analysis, 2016-2026
  • Table 2.4 Selected Recent Acquisitions in the Pre-Filled Injection Devices Industry
  • Table 3.1 BD Overview, 2016
  • Table 3.2 BD Historical Revenue by Division ($m), 2014
  • Table 3.3 BD Revenue by Division ($m), AGR (%), 2014-2015
  • Table 3.4 Medical Division Revenue ($m), 2014-2015
  • Table 3.5 BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 3.6 BD Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 3.7 BD Pharmaceutical Systems Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 3.8 Gerresheimer Employees by Region, 2015
  • Table 3.9 Gerresheimer Overview, 2016
  • Table 3.10 Gerresheimer Revenue by Division ($m), AGR ($), CAGR ($), 2014-2015
  • Table 3.11 Gerresheimer Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 3.12 Gerresheimer Pen Injectors: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 3.13 Schott Overview, 2016
  • Table 3.14 Schott Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 3.15 Schott Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 3.16 Nipro Overview, 2016
  • Table 3.17 Nipro Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 3.18 Stevanato Group/Ompi Overview, 2016
  • Table 3.19 Ompi Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 3.20 Pre-Filled Syringes: Leading Product Comparisons, 2016
  • Table 3.21 Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2016
  • Table 3.22 Unilife Overview, 2016
  • Table 3.23 Unilife: Revenue, ($m), AGR (%), CAGR (%), 2013-2015
  • Table 3.24 Revolutions Medical: RevVac Distribution Agreements, 2011-2014
  • Table 3.25 Weigao Group Pharmaceutical Packaging Products Company Overview, 2016
  • Table 3.26 Weigao: Pre-Filled Syringes Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 3.27 Weigao: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 3.28 Roselabs Group Overview, 2016
  • Table 4.1 Aptar Stelmi Overview, 2016
  • Table 4.2 Aptar Stelmi: Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 4.3 Aptar Stelmi Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 4.4 Aptar Stelmi: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 4.5 Dätwyler Overview, 2016
  • Table 4.6 Dätwyler: Sealing Solutions Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 4.7 Dätwyler Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 4.8 Dätwyler Healthcare: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 4.9 West Pharmaceutical Services Overview, 2016
  • Table 4.10 West: Selected Pharmaceutical Industry Partners, 2016
  • Table 4.11 West: Revenue by Division ($m), 2013-2015
  • Table 4.12 West Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 4.13 West: Pre-Filled Syringe and Device Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 4.14 West Pharmaceuticals: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 4.15 Tip-top Overview, 2016
  • Table 4.16 Nemera Overview, 2016
  • Table 5.1 Haselmeier Overview, 2016
  • Table 5.2 Selected Partners for the i-Pen, 2016
  • Table 5.3 Haselmeier Pre-Filled Injection Devices: SWOT Analysis, 2016-2016
  • Table 5.4 Owen Mumford Overview, 2016
  • Table 5.5 Selected Autoject Range Products, 2016
  • Table 5.6 Owen Mumford Pre-Filled Injection Devices: SWOT Analysis, 2016 to 2026
  • Table 5.7 SHL Group Overview, 2016
  • Table 5.8 SHL Group: Pen Injectors and Autoinjectors, 2016
  • Table 5.9 SHL Group Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 5.10 Ypsomed Overview, 2016
  • Table 5.11 Ypsomed: Pen Injectors and Autoinjectors, 2016
  • Table 5.12 Selected Pharmaceutical Partners for Ypsomed's Pen Injectors, 2013
  • Table 5.13 LyoTwist Injectors Available, 2016
  • Table 5.14 Ypsomed: Revenue by Division ($m), CAGR (%), 2013-2015
  • Table 5.15 Ypsomed Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 5.16 Ypsomed Delivery Devices: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 5.17 Pen Injectors: Selected Product Comparisons, 2016
  • Table 5.18 Autoinjectors: Selected Product Comparisons, 2016
  • Table 5.19 Selected Other Pen Injector and Autoinjector Manufacturers, 2016
  • Table 5.20 Bespak Injectables Overview, 2016
  • Table 6.1 Catalent Overview, 2016
  • Table 6.2 Catalent: Employees by Region, 2016
  • Table 6.3 Catalent: Revenue by Division ($m), CAGR (%), 2013-2015
  • Table 6.4 Catalent Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 6.5 Catalent Medication Delivery Solutions Division: Revenue Forecast ($m), AGR (%), CAGR (%), 2015-2026
  • Table 6.6 Hospira Overview, 2016
  • Table 6.7 Hospira Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 6.8 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
  • Table 6.9 Vetter Pharma Overview, 2016
  • Table 6.10 Vetter Pre-Filled Injection Devices: SWOT Analysis, 2016-2026
  • Table 6.11 Vetter Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
  • Table 6.12 Leading Pre-Filled Syringe CMOs: Company Comparison, 2016
  • Table 6.13 Laboratorios Farmacéuticos ROVI Overview, 2016
  • Table 6.14 Laboratorios Farmacéuticos ROVI: Revenue ($m), AGR (%), CAGR (%), 2013-2015
  • Table 6.15 AMRI Overview, 2016
  • Table 6.16 AMRI: Revenue by Division ($m), AGR (%), CAGR (%), 2013-2015
  • Table 6.17 Boehringer Ingelheim Overview, 2016
  • Table 8.1 Leading Pre-Filled Injection Device Manufacturers: Revenue Growth, 2015-2026

List of Figures

  • Figure 1.1 Global Pre-Filled Injectable Devices Market Segmentation Overview, 2016
  • Figure 2.1 Total Pre-Filled Device Manufacturing Market Forecast: Revenues ($m), 2015-2026
  • Figure 2.2 Pre-Filled Injection Device Market by Region, 2015
  • Figure 3.1 BD Historical Revenue by Division ($m), 2014
  • Figure 3.2 BD Revenue by Division ($m), 2014-2015
  • Figure 3.3 BD: Pharmaceutical Systems Revenue ($m), 2013-2015
  • Figure 3.4 BD Pharmaceutical Systems Revenue Forecast ($m), 2015-2026
  • Figure 3.5 Gerresheimer: Employees by Region, 2015
  • Figure 3.6 Gerresheimer: Revenue by Division ($m), 2014-2015
  • Figure 3.7 Gerresheimer Pen Injectors: Revenue Forecast ($m), 2015-2026
  • Figure 3.8 Schott Revenue ($m), 2013-2015
  • Figure 3.9 Unilife: Revenue ($m), 2013-2015
  • Figure 3.10 Weigao: Pre-Filled Syringes Revenue ($m), 2013-2015
  • Figure 3.11 Weigao: Revenue Forecast ($m), 2015-2026
  • Figure 4.1 Aptar Stelmi: Revenue ($m), 2013-2015
  • Figure 4.2 Aptar Stelmi: Revenue Forecast ($m), 2015-2026
  • Figure 4.3 Dätwyler: Sealing Solutions Revenue ($m), 2013-2015
  • Figure 4.4 Dätwyler Healthcare: Revenue Forecast ($m), 2015-2026
  • Figure 4.5 West: Revenue by Division ($m), 2013-2015
  • Figure 4.6 West: Pre-Filled Syringe and Device Revenue ($m), 2013-2015
  • Figure 4.7 West Pharmaceuticals: Revenue Forecast ($m), 2015-2026
  • Figure 5.1 Ypsomed: Revenue by Division ($m), 2013-2015
  • Figure 5.2 Ypsomed Delivery Devices: Revenue Forecast ($m), 2015-2026
  • Figure 6.1 Catalent: Employees by Region, 2016
  • Figure 6.2 Catalent: Revenue by Division ($m), 2013-2015
  • Figure 6.3 Catalent Medication Delivery Solutions Division: Revenue Forecast ($m), 2015-2026
  • Figure 6.4 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
  • Figure 6.5 Vetter Pre-Filled Injection Device Filling: Revenue Forecast ($m), 2015-2026
  • Figure 6.6 Laboratorios Farmacéuticos ROVI: Revenue ($m), 2013-2015
  • Figure 6.7 AMRI: Revenue by Division ($m), 2013-2015

Companies Listed

  • AbbVie
  • Actavis (formerly Watson Pharmaceuticals)
  • AdvalTech
  • Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
  • Albany Molecular Research (AMRI)
  • AluPlast
  • Amcor Glass Tubing (part of Nipro)
  • American Stelmi (part of Aptar Stelmi)
  • Amgen
  • Amylin Pharmaceuticals
  • Antares Pharma
  • Apax Partners
  • Aptar Stelmi (part of Aptargroup)
  • AptarGroup
  • Aptuit
  • AstraZeneca
  • B. Braun Medical
  • Balda Group (part of Ompi)
  • Baxter BioPharma Solutions (part of Baxter)
  • Baxter International
  • Bayer
  • BD Medico
  • Becton, Dickinson & Co. (BD)
  • Berlin-Chemie (part of Menarini Group)
  • Berry Plastics Group
  • Bespak Injectables
  • Biocon
  • Biogen Idec
  • Bionime
  • Blackstone Group
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • CAPS (Central Admixture Pharmacy Services)
  • Cardinal Health
  • Cardium Therapeutics
  • CareFusion
  • Carl Zeiss Foundation
  • Carmel Pharma
  • Catalent Pharma Solutions
  • CeifiT
  • Centers for Disease Control and Prevention (CDC) [US]
  • Centor
  • Clere (part of Ompi)
  • Columbia Engineered Rubber
  • ConnectMeSmart GmbH
  • Consort Medical
  • Corning
  • Crucell Spain
  • Daikyo Seiko
  • Dätwyler Holding
  • Debiopharm Group
  • Diagenode
  • Disetronic Group (part of Roche)
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • DS WorldMed
  • Duoject
  • DuPont
  • Elcam Medical
  • Eli Lilly
  • European Commission
  • European Medicines Agency (EMA)
  • Euticals
  • Federal Commission for Protection against Health Risks
  • Ferring Pharmaceuticals
  • Food and Drug Administration (FDA) [US]
  • Fresenius
  • Future Injection Technologies
  • Gadea Pharmaceutical Group
  • Genentech (part of Roche)
  • Genovi Pharmaceuticals Limited
  • Gerresheimer
  • Gerresheimer item (part of Gerresheimer)
  • GSK
  • Hankook Sealtech
  • Hanmi Pharmaceutical Co
  • Haselmeier
  • HealthPrize
  • HEKUMA
  • Hospira
  • Hospira One2One (part of Hospira)
  • Hyaluron Contract Manufacturing (HCM, part of AMRI)
  • Incepta Pharmaceuticals
  • Injectronics
  • Insulet
  • J&J
  • Jabil Circuit
  • Janssen Biotech (part of J&J)
  • Korea Food and Drug Administration (KFDA)
  • Laboratorios Farmacéuticos ROVI
  • LifeScan
  • Lupin Limited
  • McKesson
  • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
  • MedImmune (part of AstraZeneca)
  • Medimop Medical Projects (part of West Pharmaceutical Services)
  • Medtronic
  • Menarini Group
  • Merck & Co.
  • Merck KGaA
  • MG Sterile Products (part of Nipro)
  • MGlas (part of Nipro)
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Montagu Private Equity
  • NanoPass Technologies
  • Nemera
  • Neutral Glass and Allied Industries
  • Nipro
  • Nipro Europe (part of Nipro)
  • Nipro Glass (part of Nipro)
  • Nipro Medical (part of Nipro)
  • Novartis
  • Novo Nordisk
  • Nuova Ompi (Formerly Ompi, Italian part of Stevanato Group)
  • Nycomed (part of Takeda)
  • Nypro
  • Occupational Safety and Health Administration (OSHA) [US]
  • Ompi
  • Ompi of America (part of Stevanato Group)
  • Ompi of Brazil
  • Ompi of China
  • Optrel (part of Stevanato Group)
  • Origom
  • Osu Biopharmaceutical Manufacturing
  • Oval Medical
  • Owen Mumford
  • PA Consulting Group
  • Palatin Technologies
  • PATH
  • Pema Holding
  • Pfizer
  • Pharma-Pen (part of West Pharmaceutical Services)
  • PharmaTap
  • Pharmstandard
  • Phillips Medisize
  • Plastef Investissements
  • Polfa Tarchomin
  • Primequal
  • Revolutions Medical
  • Rexam
  • Roche
  • Roselabs Group
  • Roselabs Bioscience (part of Roselabs Group)
  • Roselabs Polymers (part of Roselabs Group)
  • ROVI CM (part of Laboratorios Farmacéuticos ROVI)
  • Rumpler Technologies
  • Safety Syringes (part of BD)
  • Sandoz (part of Novartis)
  • Sanex Packaging Connections
  • Sanofi
  • Sanofi Pasteur
  • Savient Pharmaceuticals
  • Schering-Plough (part of Merck & Co.)
  • Schott
  • Schott Kaisha
  • Sentry BioPharma Services
  • Shandong Weigao Group Medical Polymer Company
  • Shanghai Fosun Pharmaceutical
  • SHL Group
  • Smiths Group
  • Spami (part of Stevanato Group)
  • Square Pharmaceuticals
  • Stallergenes
  • Stelmi Asia (part of Aptar Stelmi)
  • Stevanato Group
  • Sungwon Medical
  • Swedish Orphan Biovitrum (Sobi)
  • Taisei Kako
  • Teva Pharmaceutical Industries
  • The Medical House
  • The Parker Institute (part of The Parker Foundation)
  • The Tech Group (part of West Pharmaceutical Services)
  • ThinFilm
  • tip-top
  • Tissue Repair Company (part of Cardium Therapeutics)
  • Tolmar
  • Tonghua Dongbao Pharmaceutical
  • Triveni Polymers
  • UCB
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA),
  • Unilife
  • US Agency for International Development
  • Vetter Pharma
  • Weigao Group Pharmaceutical Packaging Products Company
  • West Company Mexico
  • West Pharmaceutical India Packaging Private (part of West Pharmaceutical Services)
  • West Pharmaceutical Services
  • Wockhardt
  • World Health Organization (WHO)
  • Ypsomed
  • Zeon Corporation
  • Zhongding Sealtech
Back to Top